Compare Amgen, Inc. (AMGN) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs BigBearai Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while BigBearai Holdings Inc trades at $3.25 (market cap $1.57B). The key difference: Amgen, Inc. is far larger — about 124.9× BigBearai Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | BBAI | |
|---|---|---|
Market Cap | $196.12B | $1.57B |
Sector | Health | Technology |
52-Week High | $388.16 | $8.91 |
52-Week Low | $271.18 | $3.05 |
Enterprise Value | $241.41B | $1.24B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BigBear.ai (BBAI) trades at $3.27, down 1.51% amid bearish technical signals. The company shows persistent losses with a -226.69% net income margin despite steady $127M revenue. Recent Dutch approval for airport security technology highlights growth potential, but high SG&A expenses and negative cash flow from operations remain concerns. Technical indicators show oversold conditions with RSI at 25.86, though moving averages signal continued bearish pressure.
BBAI faces significant execution risks with negative profitability metrics, though analyst consensus leans neutral with 75% hold ratings. The stock's outlook depends on converting AI contract wins into sustainable profitability, with current valuation appearing rich given ongoing losses. Near-term catalysts include Q2 2026 earnings and defense contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
